Osteoporosis International

, Volume 27, Issue 3, pp 853–859

Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015

  • A. Khan
  • A. Morrison
  • A. Cheung
  • W. Hashem
  • J. Compston
Review

Abstract

Osteonecrosis of the jaw (ONJ) has been associated with the use of aminobisphosphonates and denosumab. The vast majority (>90 %) of cases occur in the oncology patient population receiving high doses of intravenous bisphosphonates or subcutaneous denosumab. The incidence of ONJ in the osteoporosis patient population is very low and is estimated at 1–90 per 100,000 patient-years of exposure. In the oncology patient population the incidence appears to be related to dose and duration of exposure, and prevalence has been estimated to be as high as 18.6 %. A number of risk factors in addition to antiresorptive therapy have been identified. These include the presence of periodontal disease, oral surgical procedures with extractions or implants, radiation therapy, chemotherapy, diabetes, glucocorticoid use, and smoking. Antiangiogenic agents appear to contribute to the risk of ONJ, however, data at this time are limited and further evidence is required prior to confirming a causal relationship. ONJ may be prevented with optimization of oral hygiene, the use of oral antimicrobial mouth rinses, as well as systemic antibiotic therapy. Individuals not responding to conservative management or in the advanced stages of ONJ may be considered for surgery, as data over the past several years have demonstrated surgical success in this patient population. Case reports have indicated that teriparatide may enhance healing. A number of experimental therapies are being evaluated and include the use of bone marrow stem cell intralesional transplantation, local application of platelet-derived growth factor, hyperbaric oxygen, tissue grafting, and low-level laser therapy. This paper summarizes the current research as well as the international consensus on the diagnosis and management of ONJ.

Keyword

Denosumab Osteonecrosis Diagnosis Treatment Bisphosphonates 

References

  1. 1.
    Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–7CrossRefPubMedGoogle Scholar
  2. 2.
    Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. JBMR 30:3–23CrossRefGoogle Scholar
  3. 3.
    Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060–4CrossRefPubMedGoogle Scholar
  4. 4.
    Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al (2014) American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg 72(10):1938–56CrossRefPubMedGoogle Scholar
  5. 5.
    Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415–23CrossRefPubMedGoogle Scholar
  6. 6.
    Khan AA, Rios LP, Sandor GK, Khan N, Peters E, Rahman MO et al (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396–402CrossRefPubMedGoogle Scholar
  7. 7.
    Ulmner M, Jarnbring F, Torring O (2014) Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg 72:76–82CrossRefPubMedGoogle Scholar
  8. 8.
    Etminan M, Aminzadeh K, Matthew IR, Brophy JM (2008) Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 35:691–5PubMedGoogle Scholar
  9. 9.
    Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C et al (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810–7CrossRefPubMedGoogle Scholar
  10. 10.
    Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC et al (2008) Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139:32–40CrossRefPubMedGoogle Scholar
  11. 11.
    Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K et al (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211–8CrossRefPubMedGoogle Scholar
  12. 12.
    Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701CrossRefPubMedGoogle Scholar
  13. 13.
    Orwoll E, Tedlbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Edocrinol Metab 97:3161–9CrossRefGoogle Scholar
  14. 14.
    Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–65CrossRefPubMedGoogle Scholar
  15. 15.
    Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4489–92Google Scholar
  16. 16.
    Al Z (2006) Bisphosphonates are associated with increased risk of jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 64:917–23CrossRefGoogle Scholar
  17. 17.
    Pazianas M, Blumentals WA, Miller PD (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 19:773–9CrossRefPubMedGoogle Scholar
  18. 18.
    Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M et al (2010) The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 141:1365–70CrossRefPubMedGoogle Scholar
  19. 19.
    Saad F, Brown JE, Van PC, Ibrahim T, Stemmer SM, Stopeck AT et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–7CrossRefPubMedGoogle Scholar
  20. 20.
    Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combineb analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082–92CrossRefPubMedGoogle Scholar
  21. 21.
    Migliorati CA, Epstein JB, Abt E, Berenson JR (2011) Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 7:34–42CrossRefPubMedGoogle Scholar
  22. 22.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–58CrossRefPubMedGoogle Scholar
  23. 23.
    Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW et al (2010) Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 30:3–23Google Scholar
  24. 24.
    Allen MR (2007) Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact 7:358–60PubMedGoogle Scholar
  25. 25.
    Allen MR (2009) Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs 189:289–94CrossRefPubMedGoogle Scholar
  26. 26.
    Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. 2015;1-6Google Scholar
  27. 27.
    Wimalawansa SJ (2008) Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 7:491–512CrossRefPubMedGoogle Scholar
  28. 28.
    Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rates. Cancer Res 62:6538–44PubMedGoogle Scholar
  29. 29.
    Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–7PubMedGoogle Scholar
  30. 30.
    Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–51CrossRefPubMedGoogle Scholar
  31. 31.
    Brunello A, Saia G, Bedogni A, Scaglione D, Basso U (2009) Worsening of osteonecrosis of the jaw during treatment with subitinib in a patient with metastatic renal cell carcinoma. Bone 44:173–5CrossRefPubMedGoogle Scholar
  32. 32.
    Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I et al (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181–8CrossRefPubMedGoogle Scholar
  33. 33.
    English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL et al (2010) A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag 6:579–83PubMedPubMedCentralGoogle Scholar
  34. 34.
    Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillón MC, Balanzategui A et al (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112:2709–12CrossRefPubMedGoogle Scholar
  35. 35.
    Katz J, Gong Y, Salmasina D, Hou W, Burkley B, Ferreira P et al (2011) Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 40:605–11CrossRefPubMedGoogle Scholar
  36. 36.
    Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A (2012) Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 17:279–87CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2010) Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 14:271–84CrossRefPubMedGoogle Scholar
  38. 38.
    Kunchur R, Goss AN (2008) The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J 53:354–7CrossRefPubMedGoogle Scholar
  39. 39.
    Lodi G, Sardella A, Salis A, Demarosi F, Rarozzi M, Carrassi A (2010) Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 68:107–10CrossRefPubMedGoogle Scholar
  40. 40.
    Bonacina R, Mariani U, Villa F, Villa A (2011) Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 77:b147PubMedGoogle Scholar
  41. 41.
    Hellstein JW, Adler RA, Edwards B et al (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243–51CrossRefPubMedGoogle Scholar
  42. 42.
    Moretti F, Pelliccioni GA, Montebugnoli L, Marchetti C (2011) A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:777–82CrossRefPubMedGoogle Scholar
  43. 43.
    Ferlito S, Puzzo S, Liardo C (2009) Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 69:e1–4CrossRefGoogle Scholar
  44. 44.
    Bashutski JD, Eber RM, Kinney JS et al (2010) Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 363:2396–405CrossRefPubMedGoogle Scholar
  45. 45.
    Subramanian G, Cohen HV, Quek SY (2011) A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:744–53CrossRefPubMedGoogle Scholar
  46. 46.
    Harper RP, Fung E (2007) Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65:573–80CrossRefPubMedGoogle Scholar
  47. 47.
    Lau AN, Adachi JD (2009) Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rjeumatol 36:1835–7CrossRefGoogle Scholar
  48. 48.
    Cheung A, Seeman E (2010) Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 363:2473–4CrossRefPubMedGoogle Scholar
  49. 49.
    Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH (2011) Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck 33:1366–71CrossRefPubMedGoogle Scholar
  50. 50.
    Narongroeknawin P, Danila MI, Humphreys LG Jr, Barasch A, Curtis JR (2010) Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dent 30:77–82CrossRefGoogle Scholar
  51. 51.
    Iwamoto J, Yago K, Sato Y, Matsumoto H (2012) Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis. Clin Drug Investig 32:547–53PubMedGoogle Scholar
  52. 52.
    Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A et al (2011) The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111:153–63CrossRefPubMedGoogle Scholar
  53. 53.
    Mucke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA et al (2011) Outcome of treatment and parameters influencing recurrence in patients with bisphosphonates-related osteonecrosis of the jaws. J Cancer Res Clin Oncol 137:907–13CrossRefPubMedGoogle Scholar
  54. 54.
    Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA, O'Connor TL (2011) Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab. Clin Breast Cancer 11:252–7CrossRefPubMedGoogle Scholar
  55. 55.
    Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S (2012) Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med 41:214–21CrossRefPubMedGoogle Scholar
  56. 56.
    Matins MA, Martins MD, Lascala CA, Curi MM, Migliorati CA, Tenis CA et al (2012) Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral Oncol 48:79–84CrossRefGoogle Scholar
  57. 57.
    Mozzati M, Gallesio G, Arata V, Pol R, Scoletta M (2012) Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol 48:469–74CrossRefPubMedGoogle Scholar
  58. 58.
    Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW et al (2012) What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 12:1573–83CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2015

Authors and Affiliations

  • A. Khan
    • 1
  • A. Morrison
    • 2
  • A. Cheung
    • 3
  • W. Hashem
    • 1
  • J. Compston
    • 4
  1. 1.McMaster UniversityHamiltonCanada
  2. 2.Dalhousie UniversityHalifaxCanada
  3. 3.University of TorontoTorontoCanada
  4. 4.Cambridge UniversityCambridgeUK

Personalised recommendations